Donate
WHAT WE FUND

Tuberculosis

Infectious diseases

At a glance

Exploring new drug combinations to tackle drug-resistant strains of TB

Lead researcher

Dr Elizabeth V.M Kigondu and Dr Paul Race

Institution

Kenya Medical Research Institute and University of Bristol, UK

Status

Awarded and preparing to start

Amount awarded

£25,860

Last updated

08/04/21

Share

Dr Elizabeth V.M Kigondu form the Kenya Medical Research Institute and Dr Paul Race from the University of Bristol will collaborate on a research project investigating the therapeutic potential of new natural drug combinations for the treatment of drug-resistant strains of TB.

Dr Elizabeth V M Kigondu Dr Elizabeth V. M. Kigondu

Tuberculosis (TB) remains one of the leading cause of morbidity and mortality world-wide, with around one-quarter of the world’s population currently estimated to be infected by TB bacteria. Treatment for TB typically takes six months and involves four antimicrobial drugs, however, their effectiveness is becoming compromised due to the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of TB. Treatment options for individuals infected with resistant strains are severely limited, and there is a pressing need to develop new anti-infective therapies that are effective against MDR/XDR strains.

Natural products are amongst the most effective sources of anti-TB drugs. For example, rifamycin, which is produced by the bacterium Amycolatopsis rifamycinica, is one of the most important drugs in use for the treatment of TB.

Dr Paul Race Dr Paul Race

In their project, Dr Kigondu and Dr Race will investigate the therapeutic potential of drug combinations incorporating newly discovered natural product antibiotics with molecules that block common MDR/XDR drug resistance mechanisms. They will carry out screening programmes and take forward successful combinations for pre-clinical evaluation. These findings will provide the basis for larger proposals and future collaborations. They hope that this approach will unlock new avenues for the development of effective MDR/XDR therapies, translating into improved clinical outcomes for TB patients.

This project has been funded by the 2020 Dorothy Temple Cross International Collaboration Grant.

Get in touch

To find out more about the research we fund and the difference it makes.

Contact us
Support us

Help change lives

We fund and support the most promising health research wherever we discover great opportunities that are not being pursued. We use our donations responsibly and ensure we make the greatest impact where it is most needed.

DONATE
Mes Res Fd Web Couple Laughing Outdoors

Latest from Twitter

@MedResFdn: 🚨Job opportunity🚨 We're looking for a Governance Manager to support our Board of Trustees and its committees, and… https://t.co/kP9KERC3x8
1 day ago